CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign
CSL Ltd CSL
News
Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
Australia's CSL to Lower Medicaid Prices Amid U.S. Expansion
CSL's Share Price Hits Six-Month High on Guidance Beat
CSL Swings to $2.58 Billion Annual Loss on Write-Downs
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
CSL Cuts Annual Guidance, Signals $5 Billion of New Impairments — Update
CSL Cuts Annual Guidance, Signals $5 Billion of New Impairments
Australia's CSL Picks Illinois for U.S. Production Expansion
CSL Shares Fall 6.5% on Earnings Miss, Surprise CEO Change
CSL Half-Year Profit Slides 80%, Holds Dividend Steady
CSL Says CEO Paul McKenzie Will Retire
Australia's CSL to Expand U.S. Production
CSL Shares Slide After Vaccine Spinoff Delayed
CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline
CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer
United States